| 9.8 0.43 (4.59%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.32 | 1-year : | 14.44 |
| Resists | First : | 10.55 | Second : | 12.36 |
| Pivot price | 8.82  |
|||
| Supports | First : | 7.61 | Second : | 6.33 |
| MAs | MA(5) : | 9.32 |
MA(20) : | 9.14  |
| MA(100) : | 5.32 |
MA(250) : | 4.03 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 65.6 |
D(3) : | 56.9 |
| RSI | RSI(14): 61.8 |
|||
| 52-week | High : | 12.36 | Low : | 2.51 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LPCN ] has closed below upper band by 3.0%. Bollinger Bands are 9.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.97 - 10.01 | 10.01 - 10.05 |
| Low: | 9.16 - 9.21 | 9.21 - 9.25 |
| Close: | 9.73 - 9.8 | 9.8 - 9.86 |
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
Wed, 18 Feb 2026
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - PR Newswire
Sat, 14 Feb 2026
Lipocine Announces Late Breaking Oral Presentation of Data from - GuruFocus
Wed, 11 Feb 2026
Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15 - Yahoo Finance
Wed, 04 Feb 2026
Lipocine (LPCN) Price Target Increased by 58.18% to 11.09 - Nasdaq
Fri, 16 Jan 2026
LPCN 1154 for postpartum depression continues clinical process after safety review - Contemporary OB/GYN
Tue, 16 Dec 2025
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 4.89e+006 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 111 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.25e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -126.7 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 933.5 % |
| Return on Equity (ttm) | -21.5 % |
| Qtrly Rev. Growth | 4.32e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -35.4 |
| EBITDA (p.s.) | 4.64516e+006 |
| Qtrly Earnings Growth | -1.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.28 |
| Price to Cash Flow | 3.49 |
| Dividend | 0 |
| Forward Dividend | 146200 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|